Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Henner

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Neurosurgery|July 1, 1995
Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasmsP C Williams, W D Henner, S Roman-Goldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1986
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trialW P Peters, J P Eder, W D Henner, et al.
Journal of the National Cancer Institute|October 5, 1988
Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumorsJ P Eder, K Antman, A Elias, et al.
Cancer Research|December 1, 1987
Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumorsW P Peters, W D Henner, L B Grochow, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 15, 1992
Humanization of an anti-p185HER2 antibody for human cancer therapyP Carter, L Presta, C M Gorman, et al.
The Journal of Biological Chemistry|December 23, 1994
Characterization of human Gadd45, a p53-regulated proteinF Carrier, M L Smith, I Bae, et al.
Archives of Dermatology|June 1, 1988
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow supportT C Shea, K H Antman, J P Eder, et al.
Biochemistry|April 30, 1996
High-level expression and characterization of a purified 142-residue polypeptide of the prion proteinI Mehlhorn, D Groth, J Stöckel, et al.
Cancer Research|July 4, 1998
Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferaseA S Morgan, P E Sanderson, R F Borch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignanciesLee S Rosen, Joseph Brown, Bernadette Laxa, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Neurosurgery|July 1, 1995
Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasmsP C Williams, W D Henner, S Roman-Goldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1986
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trialW P Peters, J P Eder, W D Henner, et al.
Journal of the National Cancer Institute|October 5, 1988
Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumorsJ P Eder, K Antman, A Elias, et al.
Cancer Research|December 1, 1987
Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumorsW P Peters, W D Henner, L B Grochow, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 15, 1992
Humanization of an anti-p185HER2 antibody for human cancer therapyP Carter, L Presta, C M Gorman, et al.
The Journal of Biological Chemistry|December 23, 1994
Characterization of human Gadd45, a p53-regulated proteinF Carrier, M L Smith, I Bae, et al.
Archives of Dermatology|June 1, 1988
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow supportT C Shea, K H Antman, J P Eder, et al.
Biochemistry|April 30, 1996
High-level expression and characterization of a purified 142-residue polypeptide of the prion proteinI Mehlhorn, D Groth, J Stöckel, et al.
Cancer Research|July 4, 1998
Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferaseA S Morgan, P E Sanderson, R F Borch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignanciesLee S Rosen, Joseph Brown, Bernadette Laxa, et al.
Pageof 8